http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2793929-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517 |
| filingDate | 2014-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc9f9cbb162afca27e17d0e0de210e59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f811184bcd368b898cfc7aaf03ea193 |
| publicationDate | 2020-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2793929-T3 |
| titleOfInvention | V1a antagonists to treat phase shift sleep disorders |
| abstract | A V1a antagonist for use in the treatment and / or prevention of phase shift sleep disorders, wherein the V1a antagonist is a compound of formula I. ** (See formula) ** wherein R1 is aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from A, R2 is H, C1-12 alkyl, unsubstituted or substituted with one or more OH, halo, cyano or C1-12 alkoxy, - (CH2) q-Ra, where Ra is phenyl or 5- or 6-membered heteroaryl, each unsubstituted or substituted with one or more substituents independently selected from A, - (CH2) rNRiRii, -C (O) -C1-12alkyl , wherein C1-12 alkyl is unsubstituted or substituted with one or more OH, halo, cyano or C1-12 alkoxy, -C (O) (CH2) qOC (O) -C1-12alkyl, -C (O ) (CH2) qNRiRii, -C (O) O-C1-12 alkyl, wherein alkyl is unsubstituted or substituted with one or more OH, halo, cyano or C1-12 alkoxy, -S (O) 2-alkyl C1-12, or -S (O) 2NRiRii, Ri and Rii are each independently H, C1-12 alkyl , or together with the nitrogen to which they are attached, form a 3- to 7-membered heterocycloalkyl containing one or two heteroatoms selected from N, O, or S, heterocycloalkyl that is unsubstituted or substituted by one or more substituents independently selected from B, q is 1, 2, 3 or 4, r is 2, 3 or 4, A is halo, cyano, OH, C1-7 alkyl, halo-C1-7 alkyl, or C1-7 alkoxy, halo-C1-7 alkoxy, or hydroxy-C1-7 alkyl, B is oxo, halo, OH, C1-7 alkyl or C1-7 alkoxy, R3 is Cl or F, or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2013-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 177.